VAX-014 is under clinical development by Vaxiion Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VAX-014’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VAX-014 overview
VAX-014 is under development for the treatment of non-muscle invasive bladder cancer (NMIBC) and other cancers including urothelial carcinoma. The drug candidate is developed based on non-antibody targeted bacterial minicell (BMC) technology. It is administered by intravesical and intratumoral route. The drug candidate targets alpha3 beta1 and alpha5 beta1 integrin protein.
Vaxiion Therapeutics overview
Vaxiion Therapeutics is a biopharmaceutical company that develops drug delivery systems. The company develops VAX014, a minicell-based biopharmaceutical that is designed to treat non-muscle invasive bladder cancer. It utilizes bacterial minicell technology to develop drug-delivery products. Vaxiion Therapeutics BMCs are small, chromosomeless, spherical bacterial particles that target, and deliver various therapeutically relevant molecules including RNAi, protein toxins, plasmids, small molecule drugs, peptides, and imaging agents into cancer cells. The company develops non-antibody and antibody targeting drug products for use in cancer treatments. Vaxiion Therapeutics is headquartered in San Diego, California, the US.
For a complete picture of VAX-014’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
